Gsk (GLAXF) Enterprise Value (2009 - 2026)
Gsk (GLAXF) recorded quarterly Enterprise Value of -$5.0 billion in Q1 2026, up 5.31% quarter-over-quarter from -$5.2 billion in Q4 2025, and up 22.18% on a YoY basis from -$4.1 billion in Q1 2025.
Gsk (GLAXF) Enterprise Value (2009 - 2026) Analysis & Trends
Gsk's Enterprise Value history runs 18 years deep, the most recent figure standing at -$5.0 billion for Q1 2026.
- In Q1 2026, Enterprise Value rose 22.18% year-over-year to -$5.0 billion; the TTM figure through Mar 2026 stood at -$5.0 billion (up 22.18% YoY), while the FY2025 annual figure was -$5.2 billion, up 10.98% from the prior year.
- Enterprise Value was -$5.0 billion for Q1 2026 at Gsk, up from -$5.2 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$382.8 million in Q2 2022 to a low of -$9.7 billion in Q4 2022.
- Historically, Enterprise Value has averaged -$5.2 billion across 5 years, with a median of -$5.0 billion in 2026.
- Biggest YoY gain for Enterprise Value was 29.0% in 2023; the steepest drop was 1153.88% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$9.7 billion in 2022, then advanced by 27.54% to -$7.1 billion in 2023, then rose by 17.08% to -$5.9 billion in 2024, then grew by 10.56% to -$5.2 billion in 2025, then advanced by 5.31% to -$5.0 billion in 2026.
- The last three Enterprise Value figures came in at -$5.0 billion (Q1 2026), -$5.2 billion (Q4 2025), and -$4.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Gsk | - | - | 7.76 Bn | -4.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.96 Bn |
| Dec 31, 2025 | -5.24 Bn |
| Sep 30, 2025 | -4.83 Bn |
| Jun 30, 2025 | -5.65 Bn |
| Mar 31, 2025 | -6.38 Bn |
| Dec 31, 2024 | -5.86 Bn |
| Sep 30, 2024 | -5.18 Bn |
| Jun 30, 2024 | -4.37 Bn |
| Mar 31, 2024 | -4.23 Bn |
| Dec 31, 2023 | -7.06 Bn |
| Sep 30, 2023 | -4.86 Bn |
| Jun 30, 2023 | -4.80 Bn |
| Mar 31, 2023 | -4.28 Bn |
| Dec 31, 2022 | -9.75 Bn |
| Sep 30, 2022 | -4.38 Bn |
| Jun 30, 2022 | -382.83 Mn |
| Mar 31, 2022 | -6.03 Bn |
| Dec 31, 2021 | 2.71 Bn |
| Sep 30, 2021 | 3.87 Bn |
| Jun 30, 2021 | 3.63 Bn |